Stock Comparison
ABT vs DXCM
Abbott Laboratories and DexCom Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$192.35B
$33.38B
P/E (TTM)
35.7
35.0
Forward P/E
20.0
34.9
Price/Sales
4.1
6.7
Price/Book
3.7
12.7
EV/EBITDA
18.6
21.2
Dividend Yield
1.66%
—
Profitability
Net Margin
13.91%
19.31%
Operating Margin
18.17%
21.45%
Return on Equity
10.60%
38.50%
Return on Assets
5.33%
10.30%
Growth (YoY)
Revenue Growth
13.00%
13.10%
Earnings Growth
-47.50%
43.60%
Price & Risk
Beta
0.6
1.4
52-Week High
$134.48
$91.48
52-Week Low
$82.56
$54.84
Analyst Target
$118.42
$93.44
Compare ABT and DXCM your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.